| Document |
Document Title |
|
WO/1993/015066A1 |
Benzopyran and other benzo-fused leukotriene B¿4? antagonists have formula (I) wherein A, n, R?1¿, R?2¿ and R?3¿ are as defined herein. The compounds of formula (I) wherein R?1¿ is c-substituted CR?4¿R?5¿-COOR?13¿ may be prepared...
|
|
WO/1993/015067A1 |
Benzopyran and other benzo-fused leukotriene B4 antagonists have formula (I) wherein R1 is a phenyl or substituted phenyl group, and A, n, R2 and R3 are as defined herein.
|
|
WO/1993/009777A1 |
The present invention relates to novel tocotrienols and tocotrienol-like compounds displaying biological activity. The tocotrienols and tocotrienol-like compounds of this invention may be conveniently obtained from biological sources or ...
|
|
WO/1993/009112A1 |
A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially u...
|
|
WO/1993/005778A1 |
A blood lipid metabolism ameliorant, in particular, a hyperlipemia inhibitor and an atherosclerosis inhibitor, containing N-(6,11-dihydrobenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1
-piperazinebutanamide or a physiologically acceptable ...
|
|
WO/1992/020658A1 |
The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof of formula (I), a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are ...
|
|
WO/1992/012133A2 |
Compounds of formula (I), wherein Q, X, R?1�, R?2�, R?9� and Z are as defined in the text, including compositions containing said compounds and a method for using them to control arthropods.
|
|
WO/1990/012785A1 |
A styrene derivative represented by general formula (I), wherein one of R¿1? and R¿2? represents vinylbenzyl, and the other represents hydrogen, lower alkyl, C¿2? to C¿5? carboxyalkyl, or phenyl; R¿3? represents hydrogen, halogen, l...
|
|
WO/1990/011303A1 |
Use of compounds as initiators for cationic polymerization by means of thermal activation or photochemical activation (UV-irradiation) or activation by electron bombardment (EB) is described. The polymerization-initiator consists of a he...
|
|
WO/1990/007494A1 |
This invention relates to a new hydroxylamine derivative exhibiting a 5-lipoxygenase inhibitory activity and represented by general formula (I) (wherein R1 stands for aryl, aryloxy, arylthio, aryl(lower)alkyl, or aryl(lower)alkoxy, R2 fo...
|
|
WO/1990/004583A1 |
A muscarinic receptor antagonist, useful in treating irritable bowel syndrome, of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is a group of formula (alpha) or (beta), where Z and Z1 are each independently hydro...
|
|
WO/1989/003212A1 |
Variously substituted 3,5-dihydroxy-6,8-nonadienoic acids and esters, are blood cholesterol lowering agents and so are useful in the prevention and treatment of cardiovascular diseases such as atherosclerosis.
|
|
WO/1987/005014A1 |
Compounds represented by general formula (I), (wherein Y-Z represents (II), -CH=CH- or -CH2CH2-, R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents hydrogen, alkyl, optionally substituted alke...
|
|
WO/1986/001203A1 |
Compounds represented by general formula (I) (wherein A represents alkylene, Y-Z represents formula (II), -CH=CH-, -CH2CH2- or formula (III), R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents...
|
|
WO/1982/001650A1 |
Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described.
|
|
JP2024503753A |
Compounds, compositions, and methods for treating neurological and mitochondrial diseases are disclosed. [Selection diagram] None
|
|
JP2023527477A |
A stereoselective synthesis of intermediates for making heterocyclic derivatives as cap-dependent endonuclease inhibitors is provided. This method of preparation has the advantages of simple operation, high yield, and relatively controll...
|
|
JP2021531269A |
The present invention relates to novel thiocycloheptin derivatives of general formula (I), in particular thiacycloalkyne sulfoimin derivatives and their synthesis. The invention also relates to the use of novel thiocycloheptin derivative...
|
|
JP2020147604A |
To design and synthesize a new NSAIA prodrug that is positively charged and can be administered transdermally.A positively-charged NSAIA prodrug is designed and synthesized which has a chemical structure 1, 2a, 2b, 2c, or 2d. A positivel...
|
|
JP6578275B2 |
The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile link...
|
|
JP2019142892A |
To provide therapeutic compositions and methods for treating or ameliorating hypercholemia and/or cholestatic liver disease.A composition for use in treatment of hypercholemia comprises an apical sodium-dependent bile acid transporter in...
|
|
JP2016138122A |
To provide a low molecular weight compound being an antagonist of chemokine receptor function.The method comprises administering to a subject an effective amount of a compound represented by formulas (I) and (II) or physiologically accep...
|
|
JP5936669B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP5937679B2 |
The present invention relates to a method for preparing zaltoprofen or a zaltoprofen derivative by a Friedel-Crafts reaction type intramolecular cyclization reaction in an industrial scale at an industrially acceptable yield and a purity...
|
|
JP5878494B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP5662618B2 |
The purpose of the present invention is to provide a novel compound with Eg5 inhibiting activity that is useful as an antitumoral agent. The present invention pertains to a compound expressed by the general formula (I) (in formula (I), A...
|
|
JP5424880B2 |
The novel positively charged pro-drugs of aryl- and heteroarylpropionic acids in the general formula (1) 'Structure 1' and general formula (2) 'Structure 2' were designed and synthesized. The compounds of the general formula (1) 'Structu...
|
|
JP5390535B2 |
The present invention provides a 1-heterodiene derivative represented by formula (2) or salt thereof: (in formula (2), W represents hydrogen atom or the like, A represents oxygen atom or the like, R 1 represents an optionally substituted...
|
|
JP2012514655A |
Fluorinated compounds and methods of making fluorinated compounds are described herein.
|
|
JP2012511027A |
The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capabl...
|
|
JP4921375B2 |
Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, OR...
|
|
JP4889920B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP2011201778A |
To provide a compound that modulates the function of TRPV1 receptor, a TRPV1 receptor modulator comprising the derivative as an active ingredient, and an agent for preventing or treating a disease involving TRPV1 receptor, such as pain.T...
|
|
JP4716980B2 |
Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes...
|
|
JP4711953B2 |
A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary bi...
|
|
JP4607331B2 |
The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R1, R2 and (R)p have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabetes, to pha...
|
|
JP4607424B2 |
The invention relates to optical devices comprising a substrate and at least one semiconductive polymer supported by said substrate, wherein said semiconductive polymer is a copolymer in which one of the repeat units is a group of formul...
|
|
JP4603276B2 |
|
|
JP4589624B2 |
The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport ...
|
|
JP2010229136A |
To provide a modulator of a chemokine receptor mechanism.The compound is expressed by formula (1), provided that, Z is expressed by formula (2).
|
|
JPWO2008133288A1 |
The present invention has the following general formula (1).(In the formula, R1Is a phenyl group or the like which may have a substituent such as a halogeno group or a C1 to C6 alkoxy group; R2aAnd R2bAre the same or different, hydrogen ...
|
|
JP2010520884A |
This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically accep...
|
|
JP4471928B2 |
|
|
JP4442931B2 |
Compounds of the formula (I) and their salts in which R1 to R6, Y1, to Y2, Y3, m and n are as defined in claim 1 are suitable as herbicides and plant growth regulators. They can be prepared analogously to known processes using intermedia...
|
|
JPWO2008050853A1 |
A therapeutic agent for irritable bowel syndrome containing a compound having an adenosine uptake inhibitory action as an active ingredient, formula (I) [in the formula, L represents -NHC (= O)-etc., R1Represents a hydrogen atom, halogen...
|
|
JP4416198B2 |
|
|
JP4395076B2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
JP4374426B2 |
The invention relates to substituted benzo(b)thiepine-1,1-dioxide derivatives and to the acid addition salts thereof. The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and Z have the cited descriptions, to the...
|
|
JP2009234958A |
To provide a method for producing a fused ring compound consisting of a benzene ring, a 7-membered ring and a benzene ring such as a dibenzo[b, f]thiepin derivative by a small number of reaction processes in a high yield, at a low cost a...
|
|
JP2008544952A |
Dibenzocycloheptane compounds (I) and their salt and solvate and its salts, are new. Dibenzocycloheptane compounds of formula (I) and their salt and solvate and its salts, are new. Either X, Y1 : CH 2, O, S, SO, SO 2or NR5; or X-Y1- : -(...
|
